ArticleEndocrine2025
Preoperative thyroglobulin antibody concentrations and prediction of papillary thyroid carcinoma recurrence.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveAutoimmune thyroiditis (AIT), a common chronic autoimmune inflammation of the thyroid, has been associated with an elevated risk of papillary thyroid carcinoma (PTC). However, the impact of AIT on the prognosis of PTC remains uncertain. As thyroid autoantibodies were indicators for AIT, this study aimed to investigate the recurrence risk in different levels of preoperative thyroid autoantibodies in PTC patients.
methodsThis retrospective study analyzed 1122 PTC patients undergoing total thyroidectomy or lobectomy. We assessed associations of preoperative antithyroglobulin (TGAb) and antithyroid peroxidase antibodies (TPOAb) with cancer recurrence using Cox regression, restricted cubic spline models and subgroup analysis.
resultsThe median follow-up for all patients was 40 months (95%CI, 37.9-41.9) and the 3-year recurrence-free survival rate was 86.6%. Elevated TGAb >15 IU/mL independently predicted cancer recurrence risk (HR, 2.56; 95% CI, 1.21-5.44; P = 0.014). In contrast, increasing TPOAb levels were associated with a trend toward decreased risk of PTC recurrence (P for trend = 0.037), though the highest quartile (TPOAb >50 IU/mL) was not independently significant after adjustment (HR, 0.69; 95% CI, 0.41-1.15; P = 0.157). In combination, TGAb > 15 IU/mL and TPOAb ≤ 50 IU/mL predicted the highest recurrence risk (HR, 4.52; 95% CI, 1.54-13.29, P = 0.006). Female patients or patients < 55 years old with TGAb > 15 IU/mL and TPOAb ≤ 50 IU/mL had more risk of recurrence (HR, 4.68, 95% CI, 1.36-16.07; P = 0.014; HR, 5.27, 95% CI, 1.54-17.98; P = 0.008).
conclusionPreoperative TGAb, but not TPOAb, is an independent prognostic factor for PTC. The elevation of preoperative TGAb correlates with an increased recurrence rate of PTC. PTC patients with elevated preoperative TGAb levels may necessitate greater clinical attention owing to higher recurrence rates, which challenges the conventional notion that PTC concomitant with AIT is invariably indolent.
Indexed as
Identifiers
40637818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.